Login to Your Account



J.P. MORGAN 2015

Gilead: Sovaldi broadly covered, negotiations on Harvoni speeding ahead

By Michael Fitzhugh
Staff Writer

Tuesday, January 13, 2015

Gilead Sciences Inc.'s president and chief operating officer, John Milligan, told attendees of the 33rd annual J.P. Morgan Healthcare Conference that the company's HCV therapy Sovaldi is now broadly covered across most of the health plans in America and is making continuing progress in Europe, providing access for more patients than ever before.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription